Authors' recommendations: Epoetin theta (Eporatio®) is recommended as an option for restricted use within NHS Wales for the treatment of adult patients with symptomatic anaemia associated with chronic renal failure only. AWMSG is of the opinion that epoetin theta (Eporatio®) is not suitable for shared care within NHS Wales for the above indication. Epoetin theta (Eporatio®) should be prescribed by brand name to avoid automatic substitution and therefore help with pharmacovigilance. Epoetin theta (Eporatio®) is not recommended for use within NHS Wales for the treatment of symptomatic anaemia in adult cancer patients with non-myeloid malignancies receiving chemotherapy. The case for clinical effectiveness of epoetin theta (Eporatio®) has not been proven in this indication.

Project Status: Completed

Year Published: 2010

URL for published report: http://www.wales.nhs.uk/sites3/docmetadata.cfm?orgid=371&id=164981&pid=24773

English language abstract: An English language summary is available

Publication Type: Not Assigned

Country: Wales, United Kingdom

Organisation Name: All Wales Medicines Strategy Group

Contact Address: All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road, Penarth, Vale of Glamorgan CF64 2XX

Contact Name: AWTTC@wales.nhs.uk

Contact Email: AWTTC@wales.nhs.uk

Copyright: AWTTC